Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant canine influenza virus strain, its preparation method and vaccine prepared therefrom

A canine influenza virus and canine influenza technology, applied in the field of bioengineering, can solve the problems of lack of preventive vaccines, increased human infection with H3N2CIV, etc., and achieve the effect of preventing or treating canine influenza and good immunogenicity

Inactive Publication Date: 2016-08-31
HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a companion animal, dogs have very close contact with humans, which also increases the risk of human infection with H3N2CIV
[0004] Vaccines are an effective means to prevent and control viral infectious diseases, while H3N2CI is an emerging infectious disease in dogs. At present, there is no vaccine to prevent this disease at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant canine influenza virus strain, its preparation method and vaccine prepared therefrom
  • Recombinant canine influenza virus strain, its preparation method and vaccine prepared therefrom
  • Recombinant canine influenza virus strain, its preparation method and vaccine prepared therefrom

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Rescue of recombinant CIV rH3N2-DL of the present invention

[0026] 1. RT-PCR amplification of HA and NA genes of H3N2 subtype canine influenza virus

[0027] Use the Axygen column virus RNA extraction kit to extract the H3N2 subtype canine influenza virus A / Canine / Liaoning / 27 / 2012 (H3N2) strain (abbreviated as CIV LN27, preserved by the Veterinary Microorganism Culture Collection Center of Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences) For RNA, see the kit instructions for specific steps. LN27cDNA was prepared by using the universal primer for reverse transcription of influenza A virus Uni-12: 5'-AGCAAAAGCAGG-3' as the reverse transcription primer. The reverse transcription system was as follows: DEPC H2O19.0μL, LN27RNA5.0μL, AMV RT buffer8.0μL, 2.5mmol / L dNTP mixture4.0μL, Uni-12 universal primer 2.0μL, RNase Inhibitor1.0μL and AMVReverse Transcriptase1.0μL, total volume 40.0μL. Mix the above reverse transcription system, ...

Embodiment 2

[0043] Example 2 Identification of biological characteristics of recombinant CIV rH3N2-DL of the present invention

[0044] 1. Tissue culture half infection dose of recombinant CIV rH3N2-DL (50%tissue culture infectious dose, TCID 50 ) Determination:

[0045] The TCID of the 5th generation recombinant CIV rH3N2-DL was measured according to the WHO influenza operation manual 50 =10 4.8 / mL, while the TCID of the 5th generation CIV LN27 virus 50 =10 2.0 / mL, the replication titer of recombinant CIV rH3N2-DL on MDCK cells was more than 2log higher than that of parental strain CIV LN27.

[0046] 2. Chicken embryo half infection dose of recombinant CIV rH3N2-DL (50% egg infectious dose, EID 50 ) Determination:

[0047] The 5th generation CIV LN27 virus and the 5th generation recombinant CIV rH3N2-DL were made 10 times in sterilized 1×PBS respectively. 5 、10 6 、10 7 、10 8 、10 9 and 10 10 For each dilution, 5 SPF chicken embryos were inoculated, 0.2 mL per embryo, placed ...

Embodiment 3

[0052] Embodiment 3 Vaccine immune effect evaluation prepared by recombinant CIV of the present invention

[0053] Inoculate SPF chicken embryos or MDCK cells with recombinant CIV rH3N2-DL (preservation number: CGMCC No.8162), harvest chicken embryo allantoic fluid or cell culture supernatant, inactivate with 1‰ formaldehyde at 4°C for 72 hours, and inoculate through chicken embryos After the identification is completely inactivated, it is used as a vaccine antigen. The rH3N2-DL antigen is mixed with GEL A adjuvant and emulsified to make a vaccine. 1ml of vaccine (containing 8μg HA antigen) and 1ml of PBS were used to immunize 4 dogs through hindlimb muscles, and 1ml of PBS emulsified with adjuvant was used to vaccinate 4 dogs in the same way as a negative control. Booster immunization 3 weeks after the first immunization, the dosage method is the same as the immunization. 10 for 2 weeks after the second immunization 6 The virulent EID50H3N2 canine influenza virus (the viru...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a recombinant canine influenza virus strain and a preparation method thereof as well as a vaccine prepared from the recombinant canine influenza virus strain. A recombinant canine influenza virus comprises HA and NA genes of a H3N2 subtype canine influenza virus and six internal genes of a H9N2 avian influenza virus including PB2, PB1, PA, NP, M and NS. The recombinant canine influenza virus strain disclosed by the invention is named after rH3N2-DL. The preservation number of the recombinant canine influenza virus strain disclosed by the invention is CGMCC No.8162. The invention further discloses the preparation method of the recombinant canine influenza virus and the vaccine prepared from the recombinant canine influenza virus. Compared with the parental strain, the recombinant canine influenza virus disclosed by the invention has high virus titer and blood congeal titer both on chick embryos and MDCK cells. Animal experimental results show that the vaccine prepared from the recombinant canine influenza virus has good immunogenicity and protective efficacy.

Description

technical field [0001] The invention relates to a recombinant virus strain, in particular to a canine influenza recombinant virus, a preparation method thereof and a vaccine prepared therefrom. The invention belongs to the technical field of bioengineering. Background technique [0002] Canine influenza (Canine influenza, CI) is an acute and highly contagious respiratory disease of dogs caused by canine influenza virus (CIV) in the Orthomyxoviridae and Influenza virus type A influenza viruses. It is a fulminant epidemic and spreads very rapidly and extensively. [0003] The current epidemic of canine influenza is mainly caused by H3N8 subtype and H3N2 subtype canine influenza virus. H3N8 subtype canine influenza is caused by the cross-species transmission of equine influenza virus, which is mainly prevalent in foreign countries. There is no report of equine influenza virus infecting dogs in my country. Since 2006, incidents of avian H3N2 subtype influenza virus infecting ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N7/00C12N15/85A61K39/145A61P31/16C12R1/93
Inventor 刘明刘春国刘大飞张云
Owner HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com